A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases.
COVID-19
Neuromuscular diseases
Prognosis
Risk factor
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
26 10 2021
26 10 2021
Historique:
received:
01
07
2021
accepted:
17
10
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Due to their health condition, patients with neuromuscular diseases (NMD) are at greater risk of developing serious complications with COVID-19. The objective of this study was to analyze the prevalence of COVID-19 among NMD patients and the risk factors for its impact and severity during the first wave of the pandemic. Clinical data were collected from NMD-COVID-19 patients, between March 25, 2020 and May 11, 2020 in an anonymous survey carried out by expert physicians from the French Health Care Network Filnemus. Physicians reported 84 patients, including: 34 with myasthenia gravis, 27 with myopathy and 23 with neuropathy. COVID-19 had no effect on NMD for 48 (58%) patients and 48 (58%) patients developed low COVID-19 severity. COVID-19 caused the death of 9 (11%) NMD patients. Diabetic patients were at greater risk of dying. Patients with diabetes, hypertension or severe forms of NMD had a higher risk of developing a moderate or severe form of COVID-19. In our cohort, corticosteroids and other immunosuppressants were not significantly associated with higher COVID-19 severity for acquired NMD. During this period, a small percentage of French NMD patients was affected by COVID-19 compared to the general French population and COVID-19 had a limited short-term effect on them. Diabetes, hypertension and a severe degree of NMD were identified as risk factors of unfavorable outcome following COVID-19. Conversely, in our cohort of patients with acquired NMD, corticosteroids or other immunosuppressants did not appear to be risk factors for more severe COVID-19.
Sections du résumé
BACKGROUND
Due to their health condition, patients with neuromuscular diseases (NMD) are at greater risk of developing serious complications with COVID-19. The objective of this study was to analyze the prevalence of COVID-19 among NMD patients and the risk factors for its impact and severity during the first wave of the pandemic. Clinical data were collected from NMD-COVID-19 patients, between March 25, 2020 and May 11, 2020 in an anonymous survey carried out by expert physicians from the French Health Care Network Filnemus.
RESULTS
Physicians reported 84 patients, including: 34 with myasthenia gravis, 27 with myopathy and 23 with neuropathy. COVID-19 had no effect on NMD for 48 (58%) patients and 48 (58%) patients developed low COVID-19 severity. COVID-19 caused the death of 9 (11%) NMD patients. Diabetic patients were at greater risk of dying. Patients with diabetes, hypertension or severe forms of NMD had a higher risk of developing a moderate or severe form of COVID-19. In our cohort, corticosteroids and other immunosuppressants were not significantly associated with higher COVID-19 severity for acquired NMD.
CONCLUSION
During this period, a small percentage of French NMD patients was affected by COVID-19 compared to the general French population and COVID-19 had a limited short-term effect on them. Diabetes, hypertension and a severe degree of NMD were identified as risk factors of unfavorable outcome following COVID-19. Conversely, in our cohort of patients with acquired NMD, corticosteroids or other immunosuppressants did not appear to be risk factors for more severe COVID-19.
Identifiants
pubmed: 34702344
doi: 10.1186/s13023-021-02090-y
pii: 10.1186/s13023-021-02090-y
pmc: PMC8547719
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
450Informations de copyright
© 2021. The Author(s).
Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Neurology. 2020 Jun 2;94(22):959-969
pubmed: 32284362
Muscle Nerve. 2021 Sep;64(3):357-361
pubmed: 34105182
Muscle Nerve. 2021 Mar;63(3):357-364
pubmed: 33280141
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Neurology. 2021 Apr 20;96(16):e2109-e2120
pubmed: 33568541
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Radiology. 2020 Apr;295(1):22-23
pubmed: 32049600
Front Neurol. 2020 Sep 11;11:1053
pubmed: 33013676
Front Neurol. 2020 Nov 26;11:588929
pubmed: 33329336
Ann Rheum Dis. 2021 Apr;80(4):527-538
pubmed: 33268442
Med Sci (Paris). 2019 Nov;35 Hors série n° 2:5-6
pubmed: 31859622
JAMA. 2020 Feb 25;323(8):709-710
pubmed: 31999307
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Med Virol. 2020 May;92(5):522-528
pubmed: 32027036